Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Excelsior BiopharmaROCO:6496 -0.40%54 Shareholder Yield % is 1.67% as of Dec. 2025, which is 178% above its 10-year median of 0.60. GuruFocus rates ROCO:6496 with a GF Score™ of 54/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 973 Drug Manufacturers companies, Excelsior Biopharma ranks better than 62.69% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Excelsior Biopharma's Shareholder Yield % was 1.67%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Excelsior Biopharma Shareholder Yield % Related Terms
Excelsior Biopharma Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Excelsior Biopharma's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6496 vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Biopharma Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Excelsior Biopharma's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Excelsior Biopharma (ROCO:6496) has a Shareholder Yield % of 1.67% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Excelsior Biopharma and its competitors. This is 178% above median its historical median of 0.60. According to the industry distribution chart, Excelsior Biopharma ranks #363 out of 973 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Excelsior Biopharma's Shareholder Yield % too high?
Excelsior Biopharma's current Shareholder Yield % of 1.67% is 178% above median its 10-year median of 0.60. The Drug Manufacturers industry median Shareholder Yield % is 0.31. Excelsior Biopharma's value of 1.67% is 438.7% above this industry median. Based on the distribution chart, Excelsior Biopharma ranks #363 out of 973 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Excelsior Biopharma has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Excelsior Biopharma ranks #363 out of 973 companies for Shareholder Yield %. This puts Excelsior Biopharma in the upper half of its industry. The industry median Shareholder Yield % is 0.31. Excelsior Biopharma's value of 1.67% is 438.7% above this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 0.31, Excelsior Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.31, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Excelsior Biopharma's current Shareholder Yield % of 1.67% is 438.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Excelsior Biopharma and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Excelsior Biopharma's current Shareholder Yield % is 1.67%, which is 178% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$25.00 — trading 30.6% below its estimated fair value. The current Shareholder Yield % is 1.67%, which is 178% above median its 10-year median of 0.60 and 438.7% above the Drug Manufacturers industry median of 0.31. Excelsior Biopharma's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current Shareholder Yield % is 1.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued.
The current stock price of NT$25.00 is trading 30.6% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Excelsior Biopharma to be Possible Value Trap.
Key valuation signals for ROCO:6496:
Shareholder Yield %: 1.67% (178% above median its 10-year median of 0.60)
GF Value™: NT$36.00 vs. price of NT$25.00 (30.6% below fair value)
Industry Position: 438.7% above the Drug Manufacturers median (#363 of 973)
No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
54GF Score
Get the complete analysis for ROCO:6496
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6496 has been successfully added to your 
